NeuroBo Pharmaceuticals Stock (NASDAQ: NRBO)

NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO), Trade Ideas

NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

CELU

CMPR

NRBO

PTON

REVB

VLCN

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday.

The Dow traded up 0.66% to 38,403.91 while the NASDAQ rose 1.01% to 15,316.80. The S&amp;P 500 also rose, gaining, 0.87% to 4,887.70.

Dow Jumps 250 Points; Honeywell Issues Weak Forecast

Movers

ALGM

ASST

BFRG

BOOT

BRTX

CACC

CHRW

CMAX

CMND

CTVA

DGII

EGHT

ELAB

ELWS

ETSY

EVAX

EVER

FBLG

FCEL

HSAI

IFBD

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

MINM

NVIV

NYCB

OGEN

PLUG

PSNY

RACE

RKLB

SPWR

SRDX

TCRT

WOLF

YOSH

ZION

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

U.S. stocks traded higher midway through trading, with the S&amp;P 500 gaining around 0.5% on Thursday.

The Dow traded up 0.23% to 38,238.99 while the NASDAQ rose 0.54% to 15,245.46. The S&amp;P 500 also rose, gaining, 0.48% to 4,868.71.

Crude Oil Gains 1%; ISM Manufacturing PMI Tops Expectations

NeuroBo Pharmaceuticals, Inc. - Common Stock

NeuroBo Pharmaceuticals Inc

Biosig Technologies, NeueHealth among healthcare movers

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Last week, the Federal Reserve&rsquo;s interest rate decision and the latest non-farm payroll (NFP) data dictated the stock market&rsquo;s performance. During heightened volatility, a handful of stocks stood out due to intense price momentum, which may continue into the coming week due to company-specific events.<br><br>Regional banks attracted renewed scrutiny after <strong>New York Community Bancorp&rsquo;s </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/nycb-stock-quote/"><strong>NYCB</strong></a></span>) disappointing quarterly earnings release. The company acquired assets from the failed <strong>Signature Bank</strong> (OTCMKTS:<span><a href="https://investorplace.com/stock-quotes/sbny-stock-quote/"><strong>SBNY</strong></a></span>) in prior years, and lingering concerns over credit quality weighed on investor sentiment towards the sector.<br><br>Stay-at-home darling <strong>Peloton Interactive</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pton-stock-quote/"><strong>PTON</strong></a></span>) also reported lackluster financial results and downwardly revised its guidance.</p>



<p>However, one pharmaceutical firm stood out from its peers thanks to positive regulatory news: <strong>NeuroBo Pharmaceuticals </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nrbo-stock-quote/"><strong>NRBO</strong></a></span>). It triggered significant share price gains and a comparatively robust balance sheet.</p>



<p>These companies have shown noteworthy momentum, warranting attention as three stocks to watch this week.</p>



<h2>New York Community Bancorp (NYCB)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/nycb-1600-300x169.jpg" alt="New York Community Bancorp logo on a smartphone screen."><div>Source: Piotr Swat / Shutterstock</div></div>


<p>New York Community Bancorp<strong> </strong>reported its <a href="https://ir.mynycb.com/news-and-events/news-releases/press-release-details/2024/NEW-YORK-COMMUNITY-BANCORP-INC.-REPORTS-RECORD-RESULTS-FOR-2023/default.aspx">Q4 2023 results</a> on January 31, <a href="https://finance.yahoo.com/news/us-bank-stocks-sink-york-145753214.html">surprising markets</a> and <a href="https://www.cnbc.com/2024/02/01/us-regional-banking-shares-tumble-for-second-straight-day.html">negatively impacting other regional banks.</a> Subsequently, <strong>Moody&rsquo;s</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/mco-stock-quote/"><strong>MCO</strong></a></span>) placed the company under review to potentially <a href="https://www.reuters.com/business/finance/moodys-puts-new-york-community-bancorp-review-downgrade-2024-02-01/">downgrade its debt rating to junk.</a></p>



<p>The company announced an earnings loss and cut its dividend by over 70% after acquiring failed Signature Bank in the previous year, accelerating existing issues. Management explained the loss and dividend reduction formed part of establishing the required capital ratios for companies with over $100 billion in assets. This necessitated setting aside over half a billion dollars in provisions and distributing less to shareholders to build reserves. Other concerning signs, such as a 16% quarterly drop in net interest income (NII), emerged. </p>



<p><strong>Jefferies </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/jef-stock-quote/"><strong>JEF</strong></a></span>), <strong>Royal Bank of Canada </strong>(OTCMKTS:<span><a href="https://investorplace.com/stock-quotes/rbcpf-stock-quote/"><strong>RBCPF</strong></a></span>), <strong>Compass Point</strong> and <strong>Deutsche Bank</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/db-stock-quote/"><strong>DB</strong></a></span>) adjusted their forecasts downwards. But in a positive signal, the company accumulated over $9 billion in cash over the past year. Excluding provisions, net profit would have been $300 million, higher than the $207 million reported previously and nearly double the prior year&rsquo;s $172 million. </p>



<p>Despite the bank issuing a statement expressing <a href="https://www.reuters.com/business/finance/us-regional-banking-shares-under-lens-after-nycb-slide-2024-02-01/#:~:text=In%20a%20late%2DThursday%20email,at%20NYCB%20were%20mostly%20unique.">confidence in share price recovery</a> once markets appreciate the value-enhancing actions, lowering the dividend yield from 6.5% to 3.5% may complicate an immediate rebound as the timing and scale of any return to prior payout levels remains uncertain.</p>



<h2>Peloton Interactive (PTON)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/pton1600-300x169.jpg" alt="Peloton (PTON stock) sign on city storefront"><div>Source: JHVEPhoto / Shutterstock.com</div></div>


<p>Peloton disappointed investors, with the company guiding that sales in the following quarter would be <a href="https://investor.onepeloton.com/static-files/34f2d1ec-4711-40dd-add3-74f40d997786">below consensus expectations.</a> Management indicated they forecasted <a href="https://finance.yahoo.com/news/peloton-tumbles-15-predicting-another-144616137.html">sales to decline</a> in the coming reporting period.<br><br>There were some positive signs, however. The company has successfully increased gross margins on connected fitness products and maintained an overall gross margin figure above 40%. Additionally, Peloton has trimmed its cash burn significantly, reducing it to $37 million from $94 million in the prior year.<br><br>The earnings report likely contributed to Peloton&rsquo;s share price reaching a record low, where it may find a temporary bottom pending new financial data. However, that will probably not emerge until the next earnings release towards the end of April. Even then, management still anticipates reporting negative EBITDA, although the loss is expected to narrow. On an optimistic note, Peloton has $737.7 million in cash reserves, down from $813.9 million last year, implying the business can sustain itself for years without needing to pursue shareholder dilution by issuing additional equity.</p>



<h2>NeuroBo Pharmaceuticals (NRBO)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600-300x169.png" alt="pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory"><div>Source: Dmitry Kalinovsky / Shutterstock.com</div></div>


<p>A press release issued on February 1 <a href="https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-announces-fda-clearance-of-ind-for-a-phase-1-clinical-trial-of-da-1726-for-the-treatment-of-obesity-302050383.html">announced</a> that the U.S. Food and Drug Administration (FDA) cleared the start of a Phase 1 clinical trial for DA-1726, an investigational new drug being developed for treating obesity. The trial will commence in the latter half of this calendar year.<br><br>One of the top 10 gainers last week, the company&rsquo;s <a href="https://finance.yahoo.com/quote/NRBO?p=NRBO&amp;.tsrc=fin-srch">share price soared 67%</a> following the announcement. It is unlikely that further momentum can be generated at this stage, as the details have now been priced in. Additionally, a rise of such scale would present an attractive opportunity for the company to issue shares to strengthen its balance sheet, inevitably diluting value. For those investors who acquired shares with a short-term holding period in mind, this may be the optimal time to secure profits.<br><br>As recounted in December 2023, the company executed a <a href="https://www.neurobopharma.com/news-releases/news-release-details/neurobo-pharmaceuticals-announces-1-8-reverse-stock-split">1-for-8 reverse stock split</a> to regain compliance with the ongoing listing requirements into <strong>Nasdaq</strong>. Historically, the company has reported its full-year financial results in late March.<br><br>With interim data from the Phase II clinical trial of DA-1241 for the treatment of non-alcoholic steatohepatitis (NASH) anticipated in the second half of this year, it is unlikely to see a similar reaction any time soon.<br><br>According to its most recently published quarterly financial report, the company had $25.8 million in cash and cash equivalents at the end of Q3 2023. Management guidance indicated this would provide sufficient capital to fund operations into Q4 2023.&#8203;</p>



<p><em>On the date of publication, Stavros Tousios did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a></em></p>
<div><p>Stavros Tousios, MBA, is the founder and chief analyst at Markets Untold. With expertise in FX, macros, equity analysis, and investment advisory, Stavros delivers investors strategic guidance and valuable insights.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/02/the-top-3-stocks-to-watch-this-week/">The Top 3 Stocks to Watch This Week</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The Top 3 Stocks to Watch This Week

NeuroBo Pharmaceuticals (NRBO) has released an update. NeuroBo Pharmaceuticals, Inc. has updated its corporate presentation and made it available o...

NeuroBo Pharmaceuticals Signals Updates in Corporate Outlook

NeuroBo stock jumps 14% on weight-loss drug update

NeuroBo Pharmaceuticals (NRBO) has provided an announcement. The Company has made a significant move by appointing Mr. Woodworth as the new Chief E...

NeuroBo Pharmaceuticals Announces Key Leadership Appointment

NeuroBo Pharmaceuticals appoints Marshall Woodworth as CFO

KB Financial, BeiGene, Legend Biotech among premarket gainers' pack

NeuroBo Phase 2a study for MASH drug  to proceed as planned

NeuroBo Pharmaceuticals GAAP EPS of -$2.46

NeuroBo Pharmaceuticals files for $150M mixed shelf

ANNX

BBAI

BFRI

BGNE

BSGM

CLRO

EDUC

EFSH

GRPH

HOLO

INBS

JZXN

LEGN

NEUE

OCEA

PIXY

RBCPF

SBNY

SIGA

SKIN

SOUN

TNON

TYRA

ZLAB

Press Releases

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity